Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Frédéric Galactéros, MDPhD, Ersi Voskaridou, Anoosha Habibi, MD PhD, Giovanna Cannas, MD, Laure Joseph, MD, Gylna Loko, MD, Mariane De Montalembert, MD PhD, Narcisse Elenga, MD PhD, Malika Benkerrou, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140265

Published: 2020

Journal Articles

Sickle-Cell Disease Patients' Attitudes Towards Their Treatment with Hydroxycarbamide

Frédéric Galactéros, MD PhD, Ersi Voskaridou, Anoosha Habibi, Giovanna Cannas, MD, Laure Joseph, MD, Stephanie Ngo, MD, Nathalie Lemonne, Emmanuelle Bernit, MD, Justine Gellen-Dautremer, MD, Gylna Loko, MD

Blood (2019) 134 (Supplement_1): 1013.

https://doi.org/10.1182/blood-2019-125673

Published: 2019

Journal Articles

Outcomes of Pregnancies in Patients with Sickle-Cell Disease : Update from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Frédéric Galactéros, MD PhD, Giovanna Cannas, MD, Pablo Bartolucci, MD PhD, Ersi Voskaridou, Laure Joseph, MD, Emmanuelle Bernit, MD, Justine Gellen-Dautremer, MD, Corinne Charneau, MD, Stephanie Ngo, MD, Anoosha Habibi

Blood (2019) 134 (Supplement_1): 891.

https://doi.org/10.1182/blood-2019-125812

Published: 2019

Journal Articles

Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide

Anoosha Habibi, MD, Elena Foïs, MD, Giovanna Cannas, MD, Jean-Antoine Ribeil, MD, Pierre Cougoul, MD, Emmanuelle Bernit, MD, Pablo Bartolucci, MD PhD, Frederic Galacteros, MDPhD

Blood (2017) 130 (Supplement 1): 2260.

https://doi.org/10.1182/blood.V130.Suppl_1.2260.2260

Published: 2017

Journal Articles

Hydroxycarbamide (HU), Sickle Cell Disease and Pregnancy, a Multicentric Retrospective Study

Laure Joseph, MD, Anoosha Habibi, MD, Giovanna Cannas, MD, Stephanie Ngo, MD, Sylvain Le Jeune, MD, Ersi Voskaridou, MD, Elena Foïs, MD, Caroline Makowski, MD, Nathalie Lemonne, MD, Narcisse Elenga, MD, Yves Ville, MD PhD, Alexandra Benachi, MDPhD, Robert Girot, MD, Marina Cavazzana, MD PhD, Jean-Antoine Ribeil, MD PhD

Blood (2016) 128 (22): 1309.

https://doi.org/10.1182/blood.V128.22.1309.1309

Published: 2016

Journal Articles

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Aline Praire, MSc, Frederic Garban, MD PhD, Claude Eric Bulabois, MD, Ibrahim Yakoub-Agha, MD PhD, Valerie Coiteux, MD, Remy Dulery, MD, Pierre-Simon Rohrlich, MDPhD, Faezeh Legrand, MD, Laurence Clement, Stephane Morisset, Stat., Giovanna Cannas, MD, Marie Y. Detrait, MD, Fiorenza Barraco, MD, Franck E. Nicolini, MD PhD, Olivier Hequet, MD

Blood (2014) 124 (21): 3916.

https://doi.org/10.1182/blood.V124.21.3916.3916

Published: 2014

Journal Articles

The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens

Marie Y. Detrait, MD, Valerie Dubois, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Nathalie Tedone, CRA, Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Lilia Gillis, MD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Mauricette Michallet

Blood (2011) 118 (21): 2038.

https://doi.org/10.1182/blood.V118.21.2038.2038

Published: 2011

Journal Articles

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Marie Y. Detrait, MD, Patrice Chevallier, MD, PhD, Mohamad Sobh, Pharm.M., Thierry Guillaume, Xavier Thomas, MD, PhD, Stephane Morisset, Stat., Nathalie Tedone, CRA, Jacques Delaunay, MD, Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Youcef Chelghoum, MD, Mohamad Mohty, Mauricette Michallet

Blood (2011) 118 (21): 1957.

https://doi.org/10.1182/blood.V118.21.1957.1957

Published: 2011

Journal Articles

Highly Significant Impact of HLA-DRB3 and HLA-DRB4 Matching on Different Unrelated Allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Marie Y. Detrait, MD, Valerie Dubois, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Nathalie Tedone, CRA, Sylvie Rey, Mauricette Michallet

Blood (2011) 118 (21): 4481.

https://doi.org/10.1182/blood.V118.21.4481.4481

Published: 2011

Journal Articles

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Helene Labussiere, MD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Jihane Fattoum, MD, PhD, Nathalie Tedone, CRA, Youcef Chelghoum, MD, Giovanna Cannas, MD, Xavier Thomas, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2011) 118 (21): 4093.

https://doi.org/10.1182/blood.V118.21.4093.4093

Published: 2011

Journal Articles

Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma

Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Taoufik Guilli, MSc, Sophie Ducastelle-Lepretre, MD, Fiorenza Barraco, MD, Youcef Chelghoum, MD, Giovanna Cannas, MD, Xavier Thomas, MD, PhD, Aline Praire, MSc, Helene Labussiere, MD, Franck E Nicolini, MD, PhD, Colette Chapuis-Celier, MD, Mauricette Michallet, MD, PhD

Blood (2010) 116 (21): 2954.

https://doi.org/10.1182/blood.V116.21.2954.2954

Published: 2010

Journal Articles

Invasive Aspergillosis: A New Important Risk Factor On Short and Long-Term Survival of AML Patients.

Blood (2009) 114 (22): 1010.

https://doi.org/10.1182/blood.V114.22.1010.1010

Published: 2009

Journal Articles

Allogeneic Hematopoietic Stem Transplantation Does Not Erase the Impact of the New Prognosis Classification in AML and the Negative Influence of Evi1 and Flt3 ITD Mutations.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Sandrine Hayette, MD, Carole Charlot, Mohamed El Hamri, PhD, Nathalie Tedone, Franck Emmanuel Nicolini, MD, PhD, Giovanna Cannas, MD, Youcef Chelghoum, MD, Emmanuelle Nicolas-Virelzier, MD, Sophie Ducastelle, MD, Fiorenza Baracco, MD, Isabelle Tigaud, MD, Xavier Thomas, MD, PhD

Blood (2009) 114 (22): 4678.

https://doi.org/10.1182/blood.V114.22.4678.4678

Published: 2009

Journal Articles

Need of Reconsideration of Mobilization Strategy in Autologous Stem Cell Transplantation for Multiple Myeloma: Results of the Positive Impact of High Number of CD34+ Infused Cells.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Benjamin Riche, PhD, Franck Emmanuel Nicolini, MD, PhD, Nicole Raus, Fiorenza Baracco, MD, Giovanna Cannas, MD, Youcef Chelghoum, MD, Emmanuelle Nicolas-Vierlizier, MD, Gilles Clapisson, Xavier Thomas, MD, Phd, Jacques Troncy, MD, Amina Zinai, DMD, MD, René Ecochard, PhD, Sophie Ducastelle, MD

Blood (2009) 114 (22): 3225.

https://doi.org/10.1182/blood.V114.22.3225.3225

Published: 2009

Journal Articles

Safety and Efficacy of FLAMSA Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation From Related and Unrelated Donors in High Risk Acute Leukemia and MDS Patients: A Study From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) Registry.

Blood (2009) 114 (22): 4335.

https://doi.org/10.1182/blood.V114.22.4335.4335

Published: 2009

Journal Articles

HLA Matching Is More Critical Than CMV Matching in Predicting Non-Relapse-Mortality of Patients Undergoing HSCT From An Unrelated Donor: A Retrospective Monocenter Study.

Roberto Crocchiolo, MD, Sophie Ducastelle, MD, Hélène Labussière, MD, Franck Emmanuel Nicolini, MD, PhD, Xavier Thomas, MD, PhD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Samia Madene, MD, Youcef Chelghoum, MD, Nathalie Tedone, Mohamad Sobh, Pharm.M, Mauricette Michallet, MD, PhD

Blood (2009) 114 (22): 4336.

https://doi.org/10.1182/blood.V114.22.4336.4336

Published: 2009

Journal Articles

Validation of Positive Effect of Posaconazole Prophylaxis During Induction Chemotherapy in AML: Study of Invasive Aspergillosis Incidence and of Risk Factors On Short and Long-Term Survival.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Stéphane Morisset, MSc, Giovanna Cannas, MD, Franck Emmanuel Nicolini, MD, PhD, Sophie Ducastelle, MD, Emmanuelle Nicolas-Virelizier, MD, Fiorenza Barraco, MD, Youcef Chelghoum, MD, Samira Kraghel, Nathalie Tedone, Mohamed El Hamri, PhD, Hélène Labussière, MD, Xavier Thomas, MD, PhD, Anne-Lise Bienvenu, Frédérique De Monbrison, Stéphane Picot, Marie-Christine Nicoll, Philippe Vanhems, MD

Blood (2009) 114 (22): 4124.

https://doi.org/10.1182/blood.V114.22.4124.4124

Published: 2009

Journal Articles

Impact of Molecular Markers and Cytogenetic Abnormalities on Long-Term Overall Survival and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) patients

Mauricette Michallet, MD, PhD, Mohamad Sobh, PhD, Xavier Thomas, MD, Carole Charlot, Fiorenza Barraco, MD, Giovanna Cannas, MD, Franck E Nicolini, MD, PhD, Emmanuelle Nicolas-virelizier, MD, Claudiu Plesa, MD, Youcef Chelghoum, MD, Jacques Troncy, MD, jean-Pierre Magaud, MD, PhD, Isabelle Tigaud, Sandrine Hayette

Blood (2008) 112 (11): 4476.

https://doi.org/10.1182/blood.V112.11.4476.4476

Published: 2008

Journal Articles

Impact of Pre-Transplantation, Mobilization and Graft Variables on Transplant Outcome after Autologus Hematopoietic Stem Cell Transplantation in Multiple Myeloma in Patients

Mauricette Michallet, MD, PhD, Quoc Hung Le, MD, Mohamad Sobh, PhD, Nicole Raus, Melissa Clarck, Jean Vial, Gilles Clapisson, Carole Paillet, Franck E Nicolini, MD, PhD, Jacques Troncy, MD, Xavier Thomas, MD, Youcef Chelghoum, MD, Emmanuelle Nicolas-Vierlizier, MD, Giovanna Cannas, MD, Claudiu Plesa, MD, Fiorenza Baracco, MD

Blood (2008) 112 (11): 5137.

https://doi.org/10.1182/blood.V112.11.5137.5137

Published: 2008

Journal Articles

Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade ® ): A Study on Efficacy, Tolerance, Survival and Time to Progression

Mauricette Michallet, MD, PhD, Mohamad Sobh, PhD, Quoc Hung Le, MD, Fiorenza Barraco, MD, Charles Dumontet, MD, PhD, Youcef Chelghoum, MD, Emmanuelle Nicolas-Virelizier, MD, Xavier Thomas, MD, Aline Praire, Claudiu Plesa, MD, Giovanna Cannas, MD, Franck Emmanuel Nicolini, MD, PhD, Jacques Troncy, MD

Blood (2008) 112 (11): 5197.

https://doi.org/10.1182/blood.V112.11.5197.5197

Published: 2008

NARROW

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Sickle-Cell Disease Patients' Attitudes Towards Their Treatment with Hydroxycarbamide

Outcomes of Pregnancies in Patients with Sickle-Cell Disease : Update from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide

Hydroxycarbamide (HU), Sickle Cell Disease and Pregnancy, a Multicentric Retrospective Study

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Highly Significant Impact of HLA-DRB3 and HLA-DRB4 Matching on Different Unrelated Allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,

Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma

Invasive Aspergillosis: A New Important Risk Factor On Short and Long-Term Survival of AML Patients.

Allogeneic Hematopoietic Stem Transplantation Does Not Erase the Impact of the New Prognosis Classification in AML and the Negative Influence of Evi1 and Flt3 ITD Mutations.

Need of Reconsideration of Mobilization Strategy in Autologous Stem Cell Transplantation for Multiple Myeloma: Results of the Positive Impact of High Number of CD34+ Infused Cells.

Safety and Efficacy of FLAMSA Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation From Related and Unrelated Donors in High Risk Acute Leukemia and MDS Patients: A Study From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) Registry.

HLA Matching Is More Critical Than CMV Matching in Predicting Non-Relapse-Mortality of Patients Undergoing HSCT From An Unrelated Donor: A Retrospective Monocenter Study.

Validation of Positive Effect of Posaconazole Prophylaxis During Induction Chemotherapy in AML: Study of Invasive Aspergillosis Incidence and of Risk Factors On Short and Long-Term Survival.

Impact of Molecular Markers and Cytogenetic Abnormalities on Long-Term Overall Survival and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Acute Myeloid Leukemia (AML) patients

Impact of Pre-Transplantation, Mobilization and Graft Variables on Transplant Outcome after Autologus Hematopoietic Stem Cell Transplantation in Multiple Myeloma in Patients

Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade ® ): A Study on Efficacy, Tolerance, Survival and Time to Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only